While there is general agreement that the currently available basal insulin analogue formulations are superior to human NPH insulin, in particular with respect to the risk of hypoglycaemia [17], there is no consensus as to which of the two available basal analogues should be recommended to initiate insulin treatment and what the potential differences are, if any, in patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.